We randomly allocated children 5-17 years of age to receive trivalent inactivated influenza vaccine ( TIV ) or placebo from September 2009 through January 2010 , and then conducted follow-up for 3 years including regular collection of sera , symptom diaries , and collection of nose and throat swabs during illness episodes in participants or their household members .